Medical journal editorial refutes WHO finding on Gilead's remdesivir for COVID-19
kathmandupost.com · Thu Dec 03 05:19:52 UTC 2020
The release in October of the trial’s summary findings sparked a reevaluation by some of the utility of remdesivir, which was shown to shorten COVID-19 hospitals stays by five days compared with a placebo in an earlier U.S. government-run trial.
An editorial in the influential New England Journal of Medicine cites problems with a World Health Organization (WHO) study that found Gilead Sciences Inc’s antiviral remdesivir failed to improve COVID-19 survival, and said it does not refute trials that demonstrated benefits of the drug in treating the illness.
Read full story at source (kathmandupost.com)